-
Keeping “InMotion” to Combat Parkinson’s Disease
January 27, 2016
… living with movement disorders. This inspired her to become a founding partner of InMotion , located in Cleveland, … the impossible possible — building a community center where the stigma of PD is left at the door, and all services … staff and certainly plan to come to Cleveland for a visit to see it firsthand! Inspired to learn more? Visit …
-
“We All Have the Power to Move the Ball Forward”: Michael J. Fox Honored with ‘Yolanda D. King Higher Ground Award’
January 26, 2024
… Known for his signature optimism and tireless work toward helping to advance scientific progress through The … month, The King Center released its annual list of “Beloved Community Award” winners to an impressive group of changemakers in government, business, …
-
Having Happy Holidays with Parkinson’s
December 20, 2023
… and reconnection with those we love. They may also come with the stress of travel, disruptions to your regular routine or even loneliness. For those living … watch our Ask the MD video and download our free guide on visiting family members who have Parkinson’s . The guide was …
-
Calpain Inhibitors to treat Parkinsons Disease
… Thus, inhibition of calpain using selective, targeted inhibitors which cross the blood brain barrier and can be … act as effective therapeutic agents in delaying and/or preventing the onset of symptoms in PD. Two such inhibitors, … a legitimate target in the prevention of PD. Anticipated Outcome: It is anticipated that in this initial investigation …
-
Leading Foundations Publish Recommendations to Accelerate Drug Repurposing for Neurodegenerative Diseases
June 26, 2014
… sectors and highlights the unique challenges and lack of commercial incentives for testing approved drugs in new … indications, like Alzheimer's or Parkinson's disease, where they might be beneficial. "Approved drugs generally … patient populations. The full paper can be accessed by visiting the Annals of Clinical and Translational Neurology …
-
Kynurenine 3-monooxygenase (KMO) as a Target to Develop Drugs to Block Progression of Parkinson's Disease
… the enzyme kynurenine 3-monooxygenase (KMO) as a target to develop drugs to treat PD (PD). KMO is expressed in cells involved in inflammation, which is … to the clinic to treat patients with PD. Anticipated Outcome: We expect to determine whether inhibiting KMO is a …